Skip to content
Menu

Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.

Read at benzinga.com

← All stock news